GlassScriptPhysician profile
Manprit Dhillon
NPI 1710963038
$2,874.88
in general payments reported to CMS, 2019-2025
40 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $26.38 · 2021: $165 · 2022: $364 · 2023: $445 · 2024: $626 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.07 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $402.26 | 2023-2025 | |
| Biogen, INC. | $267.96 | 2022-2025 | Vumerity, Tysabri |
| Ucb, INC. | $235.40 | 2019-2025 | Rystiggo |
| Eisai INC. | $181.02 | 2025 | |
| Abbott Laboratories | $171.86 | 2021-2022 | |
| Lilly USA, LLC | $171.22 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $138.26 | 2023-2025 | Austedo Xr, Austedo |
| Cerapedics INC. | $116.77 | 2022 | |
| Lundbeck LLC | $87.82 | 2023-2025 | Vyepti |
| Genentech USA, INC. | $82.08 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $72.68 | 2022-2023 | Qulipta |
| Integra Lifesciences Corporation | $68.22 | 2019-2021 | |
| Neurelis, INC. | $68.17 | 2024-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $66.64 | 2019-2025 | Ultomiris |
| Cycle Pharmaceuticals INC | $63.99 | 2025 | Bafiertam, Tascenso Odt |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $60.30 | 2025 | |
| Octapharma USA, INC. | $55.63 | 2024-2025 | Panzyga |
| Grifols USA, LLC | $51.25 | 2019-2025 | Gamunex-C |
| Stryker Corporation | $41.61 | 2019-2020 | |
| Microtransponder, INC. | $34.54 | 2023-2024 | |
| Argenx US, INC. | $34.34 | 2022 | |
| Boston Scientific Corporation | $33.77 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $32.90 | 2025 | Daybue |
| Ceribell, INC. | $29.57 | 2023 | Ceribell Rapid Response Eeg |
| Amneal Pharmaceuticals LLC | $29.06 | 2023 | Rytary |
| Jazz Pharmaceuticals INC. | $26.56 | 2025 | |
| Merck Sharp & Dohme LLC | $24.58 | 2023 | Welireg |
| Ani Pharmaceuticals, INC. | $24.27 | 2023 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $22.18 | 2024 | Onpattro |
| Livanova USA, INC. | $21.80 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Si-Bone, INC. | $20.89 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.84 | 2024 | Acthar |
| Medtronic, INC. | $19.69 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.86 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.02 | 2025 | Rexulti |
| Amgen INC. | $14.93 | 2019 | |
| Travere Therapeutics, INC. | $14.73 | 2023 | Cholbam |
| Ethicon US, LLC | $13.49 | 2022 | |
| Kls-Martin L.P. | $11.27 | 2022 | |
| Forte Bio-Pharma LLC | $9.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manprit Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.